vs

Side-by-side financial comparison of INTELLIGENT BIO SOLUTIONS INC. (INBS) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.

PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $896.8K, roughly 1.5× INTELLIGENT BIO SOLUTIONS INC.). INTELLIGENT BIO SOLUTIONS INC. runs the higher net margin — -298.6% vs -417.9%, a 119.3% gap on every dollar of revenue. On growth, INTELLIGENT BIO SOLUTIONS INC. posted the faster year-over-year revenue change (47.6% vs -3.2%). INTELLIGENT BIO SOLUTIONS INC. produced more free cash flow last quarter ($-1.6M vs $-6.3M). Over the past eight quarters, INTELLIGENT BIO SOLUTIONS INC.'s revenue compounded faster (4.3% CAGR vs -9.7%).

The Institute of Robotics and Intelligent Systems (IRIS) is part of the ETH Zurich, Switzerland. It replaced the existing Institute of Robotics, of the ETH Zurich in October 2002, when Prof. Bradley J. Nelson moved from the University of Minnesota, United States, to ETH Zurich, and succeeded the Prof. Dr. Gerhard Schweitzer.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...

INBS vs PSTV — Head-to-Head

Bigger by revenue
PSTV
PSTV
1.5× larger
PSTV
$1.4M
$896.8K
INBS
Growing faster (revenue YoY)
INBS
INBS
+50.8% gap
INBS
47.6%
-3.2%
PSTV
Higher net margin
INBS
INBS
119.3% more per $
INBS
-298.6%
-417.9%
PSTV
More free cash flow
INBS
INBS
$4.7M more FCF
INBS
$-1.6M
$-6.3M
PSTV
Faster 2-yr revenue CAGR
INBS
INBS
Annualised
INBS
4.3%
-9.7%
PSTV

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
INBS
INBS
PSTV
PSTV
Revenue
$896.8K
$1.4M
Net Profit
$-2.7M
$-5.7M
Gross Margin
51.3%
Operating Margin
-293.9%
-420.0%
Net Margin
-298.6%
-417.9%
Revenue YoY
47.6%
-3.2%
Net Profit YoY
-19.0%
-46.4%
EPS (diluted)
$-2.82
$0.95

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INBS
INBS
PSTV
PSTV
Q4 25
$896.8K
$1.4M
Q3 25
$1.1M
$1.4M
Q2 25
$843.9K
$1.4M
Q1 25
$728.9K
$1.1M
Q4 24
$607.5K
$1.4M
Q3 24
$872.3K
$1.5M
Q2 24
$727.8K
$1.3M
Q1 24
$823.8K
$1.7M
Net Profit
INBS
INBS
PSTV
PSTV
Q4 25
$-2.7M
$-5.7M
Q3 25
$-3.0M
$-4.4M
Q2 25
$-3.1M
$5.2M
Q1 25
$-2.5M
$-17.4M
Q4 24
$-2.2M
$-3.9M
Q3 24
$-2.7M
$-2.9M
Q2 24
$-2.8M
$-2.9M
Q1 24
$-3.0M
$-3.3M
Gross Margin
INBS
INBS
PSTV
PSTV
Q4 25
51.3%
Q3 25
46.6%
Q2 25
39.8%
Q1 25
46.8%
Q4 24
36.7%
Q3 24
39.8%
Q2 24
Q1 24
21.7%
Operating Margin
INBS
INBS
PSTV
PSTV
Q4 25
-293.9%
-420.0%
Q3 25
-269.8%
-320.8%
Q2 25
-367.5%
-110.6%
Q1 25
-350.3%
-333.9%
Q4 24
-372.8%
-276.2%
Q3 24
-312.4%
-260.9%
Q2 24
-386.3%
-289.1%
Q1 24
-358.6%
-196.7%
Net Margin
INBS
INBS
PSTV
PSTV
Q4 25
-298.6%
-417.9%
Q3 25
-268.3%
-316.6%
Q2 25
-366.2%
370.6%
Q1 25
-349.0%
-1643.2%
Q4 24
-370.3%
-276.4%
Q3 24
-307.9%
-197.4%
Q2 24
-382.5%
-229.9%
Q1 24
-361.5%
-194.5%
EPS (diluted)
INBS
INBS
PSTV
PSTV
Q4 25
$-2.82
$0.95
Q3 25
$-0.35
$-0.04
Q2 25
$4.10
$-0.01
Q1 25
$-0.44
$-1.19
Q4 24
$-4.96
$-0.51
Q3 24
$-0.70
$-0.37
Q2 24
$9.60
$-0.71
Q1 24
$-1.43
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INBS
INBS
PSTV
PSTV
Cash + ST InvestmentsLiquidity on hand
$740.4K
$8.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$11.1M
$4.0M
Total Assets
$17.7M
$16.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INBS
INBS
PSTV
PSTV
Q4 25
$740.4K
$8.6M
Q3 25
$1.7M
$16.6M
Q2 25
$1.0M
$6.9M
Q1 25
$2.8M
$9.9M
Q4 24
$2.2M
$3.6M
Q3 24
$4.0M
$4.8M
Q2 24
$6.3M
$8.4M
Q1 24
$9.4M
$3.2M
Stockholders' Equity
INBS
INBS
PSTV
PSTV
Q4 25
$11.1M
$4.0M
Q3 25
$3.6M
$5.1M
Q2 25
$3.0M
$3.0M
Q1 25
$5.1M
$-23.6M
Q4 24
$4.4M
$-8.9M
Q3 24
$6.1M
$-5.2M
Q2 24
$8.3M
$-7.6M
Q1 24
$11.1M
$-4.8M
Total Assets
INBS
INBS
PSTV
PSTV
Q4 25
$17.7M
$16.3M
Q3 25
$10.0M
$18.7M
Q2 25
$8.2M
$10.3M
Q1 25
$9.6M
$12.1M
Q4 24
$8.7M
$6.6M
Q3 24
$11.7M
$7.0M
Q2 24
$13.8M
$11.2M
Q1 24
$17.0M
$5.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INBS
INBS
PSTV
PSTV
Operating Cash FlowLast quarter
$-1.6M
$-6.3M
Free Cash FlowOCF − Capex
$-1.6M
$-6.3M
FCF MarginFCF / Revenue
-182.4%
-459.9%
Capex IntensityCapex / Revenue
7.6%
2.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-20.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INBS
INBS
PSTV
PSTV
Q4 25
$-1.6M
$-6.3M
Q3 25
$-2.8M
$-2.5M
Q2 25
$-2.2M
$-5.8M
Q1 25
$-2.8M
$-6.2M
Q4 24
$-2.3M
$-1.2M
Q3 24
$-2.4M
$-3.7M
Q2 24
$-2.9M
$-1.1M
Q1 24
$-2.4M
$-4.5M
Free Cash Flow
INBS
INBS
PSTV
PSTV
Q4 25
$-1.6M
$-6.3M
Q3 25
$-2.9M
$-2.6M
Q2 25
$-5.8M
Q1 25
$-6.2M
Q4 24
$-1.2M
Q3 24
$-3.7M
Q2 24
$-1.2M
Q1 24
$-4.6M
FCF Margin
INBS
INBS
PSTV
PSTV
Q4 25
-182.4%
-459.9%
Q3 25
-262.4%
-184.3%
Q2 25
-417.6%
Q1 25
-583.1%
Q4 24
-86.5%
Q3 24
-253.7%
Q2 24
-96.2%
Q1 24
-271.5%
Capex Intensity
INBS
INBS
PSTV
PSTV
Q4 25
7.6%
2.2%
Q3 25
6.3%
1.9%
Q2 25
0.5%
Q1 25
0.3%
Q4 24
0.8%
Q3 24
1.0%
Q2 24
6.3%
Q1 24
2.4%
Cash Conversion
INBS
INBS
PSTV
PSTV
Q4 25
Q3 25
Q2 25
-1.13×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons